(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
NASA's make-or-break moon shot - 2Safeguarding Your Senior Protection Against Extortion and Tricks.
- 3Several injured as man threatens attack on German high-speed train
- 4Recent studies prove the ancient practice of nasal irrigation is effective at fighting the common cold
- 5The Best Internet based Retailers for Style and Frill
- Ministry: New German petrol price regulation takes effect on April 1
- Polls open in tense Uganda election amid widespread delays
- South Africa pushes for $200B investment
- Spanish police and soldiers track boars, reinforce farm security amid swine fever outbreak
- 6 Famous Cell phone Brands All over The Planet
- The Main 10 Natural life Protection Associations
- 3 moms, 3 countries, 1 very familiar problem: Why child care costs still don't add up for families
- NASA's Artemis 2 astronauts are cruising to the moon. So why are they doing CPR tests today?
- 35 million tons of food go to waste yearly in the US. Experts share tips to help stop it
